Linked Life Data

19824795

Source:http://linkedlifedata.com/resource/pubmed/id/19824795

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2009-10-14
pubmed:abstractText
African trypanosomiasis causes devastating effects on human populations and livestock herds in large parts of sub-Saharan Africa. Control of the disease is hampered by the lack of any efficient vaccination results in a field setting, and the severe side effects of current drug therapies. In addition, with the exception of Trypanosoma brucei gambiense infections, the diagnosis of trypanosomiasis has to rely on microscopic analysis of blood samples, as other specific tools are nonexistent. However, new developments in biotechnology, which include loop-mediated isothermal amplification as an adaptation to conventional PCR, as well as the antibody engineering that has allowed the development of Nanobody technology, offer new perspectives in both the detection and treatment of trypanosomiasis. In addition, recent data on parasite-induced B-cell memory destruction offer new insights into mechanisms of vaccine failure, and should lead us towards new strategies to overcome trypanosome defenses operating against the host immune system.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1746-0921
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1075-87
pubmed:dateRevised
2010-12-30
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
African trypanosomiasis and antibodies: implications for vaccination, therapy and diagnosis.
pubmed:affiliation
Department of Molecular & Cellular Interactions, Flanders Institute for Biotechnology, Rijvisschestraat 120, B-9052 Ghent, Belgium. stemagez@vub.ac.be
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't